AI-generated summary
This randomized, placebo-controlled trial compared transmeatal low-power laser stimulation at 650 nm plus betahistine with a placebo device plus betahistine for tinnitus over 10 weeks, with 43 patients completing treatment. The authors report that both groups improved on some symptom scores, but the laser group did not differ significantly from the placebo group, so they conclude the laser did not show significant efficacy.
- Participants
- 43
- Who or what was studied
- Patients with persistent subjective tinnitus recruited from outpatient clinics
- Wavelengths
- 650 nm
- Limits stated in the abstract
- The abstract does not report the number of patients randomized per group or describe any limits of the sample size or follow-up beyond the 10-week period.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 650 nM
- Power
- 5 mW
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Tinnitus, Laser, Visual analogue scale, GRADE, Placebo-controlled, Control group, Depression, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.